 Joshua Barocas
Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 27 | 2023 | 413 | 9.140 |
Why?
| | Drug Overdose | 19 | 2023 | 292 | 6.060 |
Why?
| | Substance Abuse, Intravenous | 11 | 2022 | 99 | 5.630 |
Why?
| | Hepatitis C | 10 | 2022 | 219 | 3.970 |
Why?
| | Endocarditis | 6 | 2023 | 32 | 3.350 |
Why?
| | Analgesics, Opioid | 19 | 2023 | 773 | 2.420 |
Why?
| | Pharmaceutical Preparations | 6 | 2021 | 168 | 2.360 |
Why?
| | Buprenorphine | 8 | 2023 | 134 | 2.190 |
Why?
| | Hepatitis C, Chronic | 4 | 2021 | 151 | 2.100 |
Why?
| | Epidemics | 3 | 2022 | 69 | 1.980 |
Why?
| | Endocarditis, Bacterial | 4 | 2023 | 36 | 1.940 |
Why?
| | Substance-Related Disorders | 9 | 2023 | 947 | 1.890 |
Why?
| | Hepacivirus | 8 | 2022 | 229 | 1.800 |
Why?
| | HIV Infections | 10 | 2022 | 2469 | 1.630 |
Why?
| | Cost-Benefit Analysis | 10 | 2023 | 545 | 1.430 |
Why?
| | Soft Tissue Infections | 2 | 2021 | 30 | 1.420 |
Why?
| | Drug Users | 3 | 2022 | 41 | 1.390 |
Why?
| | Buprenorphine, Naloxone Drug Combination | 3 | 2022 | 9 | 1.350 |
Why?
| | Prisoners | 2 | 2022 | 124 | 1.340 |
Why?
| | Central Nervous System Stimulants | 2 | 2022 | 139 | 1.310 |
Why?
| | Anti-Infective Agents | 2 | 2022 | 225 | 1.250 |
Why?
| | Naloxone | 2 | 2021 | 97 | 1.170 |
Why?
| | Humans | 78 | 2023 | 114714 | 1.120 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 340 | 1.120 |
Why?
| | Coronavirus Infections | 3 | 2020 | 332 | 1.120 |
Why?
| | Housing | 3 | 2023 | 114 | 1.080 |
Why?
| | Fentanyl | 2 | 2023 | 66 | 1.030 |
Why?
| | Massachusetts | 7 | 2023 | 134 | 0.990 |
Why?
| | Opiate Substitution Treatment | 5 | 2022 | 98 | 0.970 |
Why?
| | Referral and Consultation | 3 | 2022 | 632 | 0.940 |
Why?
| | Patient Isolation | 2 | 2021 | 18 | 0.930 |
Why?
| | Antiviral Agents | 5 | 2022 | 646 | 0.880 |
Why?
| | Substance Abuse Treatment Centers | 2 | 2020 | 42 | 0.880 |
Why?
| | Narcotic Antagonists | 4 | 2022 | 136 | 0.860 |
Why?
| | Health Personnel | 2 | 2020 | 574 | 0.850 |
Why?
| | Mass Screening | 6 | 2020 | 1003 | 0.850 |
Why?
| | Preventive Health Services | 2 | 2020 | 135 | 0.800 |
Why?
| | Prevalence | 10 | 2023 | 2249 | 0.790 |
Why?
| | Crisis Intervention | 1 | 2021 | 29 | 0.780 |
Why?
| | Hospital Administration | 1 | 2021 | 21 | 0.780 |
Why?
| | Hospitalization | 7 | 2022 | 1751 | 0.760 |
Why?
| | Liver Cirrhosis | 2 | 2022 | 228 | 0.760 |
Why?
| | United States | 16 | 2023 | 12176 | 0.760 |
Why?
| | Criminal Law | 1 | 2021 | 28 | 0.760 |
Why?
| | Public Health | 3 | 2023 | 434 | 0.750 |
Why?
| | Adult | 27 | 2023 | 30543 | 0.750 |
Why?
| | Convalescence | 1 | 2021 | 15 | 0.750 |
Why?
| | Hospital Units | 1 | 2021 | 23 | 0.740 |
Why?
| | Communicable Diseases | 2 | 2021 | 129 | 0.740 |
Why?
| | Health Communication | 1 | 2021 | 41 | 0.730 |
Why?
| | Residential Treatment | 1 | 2020 | 30 | 0.720 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2022 | 179 | 0.680 |
Why?
| | Safety-net Providers | 1 | 2021 | 95 | 0.680 |
Why?
| | Male | 32 | 2023 | 55558 | 0.670 |
Why?
| | Immunization Programs | 1 | 2020 | 205 | 0.630 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1078 | 0.630 |
Why?
| | Needle-Exchange Programs | 2 | 2015 | 7 | 0.620 |
Why?
| | Research Design | 2 | 2023 | 931 | 0.620 |
Why?
| | Female | 30 | 2023 | 59485 | 0.580 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 87 | 0.580 |
Why?
| | Decision Support Techniques | 1 | 2021 | 351 | 0.570 |
Why?
| | Sustained Virologic Response | 1 | 2017 | 33 | 0.570 |
Why?
| | Mental Disorders | 2 | 2022 | 889 | 0.570 |
Why?
| | Delivery of Health Care | 2 | 2021 | 833 | 0.570 |
Why?
| | Social Determinants of Health | 1 | 2019 | 135 | 0.560 |
Why?
| | Young Adult | 11 | 2022 | 10462 | 0.550 |
Why?
| | Zinc | 1 | 2019 | 257 | 0.540 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2019 | 228 | 0.540 |
Why?
| | Outpatients | 2 | 2020 | 327 | 0.530 |
Why?
| | Pandemics | 8 | 2022 | 1319 | 0.530 |
Why?
| | Anti-HIV Agents | 1 | 2022 | 666 | 0.520 |
Why?
| | Guidelines as Topic | 1 | 2017 | 244 | 0.520 |
Why?
| | Monte Carlo Method | 3 | 2021 | 137 | 0.500 |
Why?
| | Criminals | 1 | 2015 | 29 | 0.490 |
Why?
| | Emergency Medical Services | 1 | 2022 | 587 | 0.490 |
Why?
| | Education | 1 | 2015 | 95 | 0.480 |
Why?
| | Blastomyces | 1 | 2014 | 7 | 0.470 |
Why?
| | Blastomycosis | 1 | 2014 | 8 | 0.470 |
Why?
| | Boston | 4 | 2021 | 75 | 0.450 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2022 | 755 | 0.450 |
Why?
| | HIV Seropositivity | 1 | 2014 | 109 | 0.450 |
Why?
| | Advance Directives | 1 | 2014 | 69 | 0.450 |
Why?
| | Peritonitis | 1 | 2014 | 76 | 0.450 |
Why?
| | Alcohol Drinking | 1 | 2019 | 654 | 0.440 |
Why?
| | Middle Aged | 15 | 2023 | 26746 | 0.430 |
Why?
| | Adolescent | 11 | 2022 | 17808 | 0.400 |
Why?
| | Retrospective Studies | 8 | 2022 | 12512 | 0.390 |
Why?
| | Quarantine | 2 | 2021 | 24 | 0.370 |
Why?
| | Injections | 2 | 2021 | 159 | 0.370 |
Why?
| | Vulnerable Populations | 2 | 2021 | 133 | 0.340 |
Why?
| | Health Services Accessibility | 3 | 2022 | 763 | 0.320 |
Why?
| | Risk-Taking | 2 | 2021 | 333 | 0.310 |
Why?
| | Kidney Transplantation | 1 | 2014 | 541 | 0.310 |
Why?
| | Harm Reduction | 2 | 2020 | 24 | 0.300 |
Why?
| | Coinfection | 2 | 2019 | 120 | 0.300 |
Why?
| | Cohort Studies | 4 | 2021 | 4899 | 0.270 |
Why?
| | Wisconsin | 3 | 2014 | 91 | 0.260 |
Why?
| | Risk Factors | 4 | 2021 | 8626 | 0.260 |
Why?
| | Ohio | 2 | 2022 | 135 | 0.250 |
Why?
| | Patient Acceptance of Health Care | 3 | 2023 | 679 | 0.240 |
Why?
| | Health Policy | 3 | 2022 | 334 | 0.230 |
Why?
| | Primary Health Care | 3 | 2023 | 1515 | 0.220 |
Why?
| | Inpatients | 3 | 2022 | 378 | 0.210 |
Why?
| | Cities | 1 | 2023 | 80 | 0.210 |
Why?
| | Life Expectancy | 1 | 2023 | 51 | 0.210 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 4406 | 0.210 |
Why?
| | Colorectal Neoplasms | 1 | 2009 | 621 | 0.210 |
Why?
| | Age Factors | 2 | 2020 | 2889 | 0.210 |
Why?
| | Quality-Adjusted Life Years | 2 | 2020 | 101 | 0.200 |
Why?
| | Quality of Life | 3 | 2022 | 2357 | 0.200 |
Why?
| | Delphi Technique | 1 | 2022 | 160 | 0.200 |
Why?
| | Immunogenicity, Vaccine | 1 | 2022 | 25 | 0.200 |
Why?
| | Arkansas | 1 | 2021 | 13 | 0.200 |
Why?
| | Ambulances | 1 | 2022 | 50 | 0.200 |
Why?
| | International Cooperation | 1 | 2022 | 172 | 0.200 |
Why?
| | Bayes Theorem | 1 | 2023 | 331 | 0.200 |
Why?
| | Naltrexone | 2 | 2021 | 83 | 0.190 |
Why?
| | Models, Economic | 1 | 2021 | 48 | 0.190 |
Why?
| | Needle Sharing | 1 | 2021 | 9 | 0.190 |
Why?
| | Markov Chains | 1 | 2021 | 114 | 0.190 |
Why?
| | Aged | 6 | 2021 | 19079 | 0.190 |
Why?
| | Interrupted Time Series Analysis | 1 | 2021 | 44 | 0.180 |
Why?
| | Costs and Cost Analysis | 1 | 2021 | 195 | 0.180 |
Why?
| | Drug Resistance, Viral | 2 | 2022 | 99 | 0.180 |
Why?
| | Prescriptions | 1 | 2021 | 60 | 0.180 |
Why?
| | Homosexuality, Male | 1 | 2022 | 170 | 0.180 |
Why?
| | Health Services | 1 | 2021 | 103 | 0.180 |
Why?
| | Sex Factors | 2 | 2020 | 1717 | 0.180 |
Why?
| | Drug Compounding | 1 | 2021 | 89 | 0.180 |
Why?
| | Betacoronavirus | 2 | 2020 | 252 | 0.180 |
Why?
| | Intersectoral Collaboration | 1 | 2020 | 56 | 0.180 |
Why?
| | Social Isolation | 1 | 2020 | 52 | 0.170 |
Why?
| | Patient Advocacy | 1 | 2020 | 66 | 0.170 |
Why?
| | Prescription Drugs | 1 | 2021 | 116 | 0.170 |
Why?
| | Communicable Disease Control | 1 | 2020 | 67 | 0.170 |
Why?
| | Demography | 1 | 2020 | 262 | 0.170 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 87 | 0.170 |
Why?
| | Russia | 1 | 2019 | 9 | 0.170 |
Why?
| | Public Health Administration | 1 | 2020 | 75 | 0.170 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2019 | 17 | 0.170 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2022 | 175 | 0.170 |
Why?
| | Age Distribution | 2 | 2018 | 339 | 0.160 |
Why?
| | Sex Distribution | 2 | 2018 | 335 | 0.160 |
Why?
| | Needs Assessment | 1 | 2020 | 313 | 0.160 |
Why?
| | Medicaid | 1 | 2022 | 407 | 0.160 |
Why?
| | Narcotics | 1 | 2018 | 44 | 0.150 |
Why?
| | Urban Population | 1 | 2021 | 398 | 0.150 |
Why?
| | Child | 5 | 2021 | 18350 | 0.150 |
Why?
| | Surgeons | 1 | 2022 | 238 | 0.150 |
Why?
| | Mental Health Services | 1 | 2021 | 316 | 0.150 |
Why?
| | Rural Population | 1 | 2021 | 446 | 0.140 |
Why?
| | Uridine Monophosphate | 1 | 2017 | 15 | 0.140 |
Why?
| | Proportional Hazards Models | 1 | 2020 | 1080 | 0.140 |
Why?
| | Fluorenes | 1 | 2017 | 38 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 560 | 0.140 |
Why?
| | Obesity | 1 | 2009 | 2513 | 0.140 |
Why?
| | Sofosbuvir | 1 | 2017 | 54 | 0.140 |
Why?
| | Computer Simulation | 1 | 2021 | 878 | 0.140 |
Why?
| | Ribavirin | 1 | 2017 | 89 | 0.130 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 462 | 0.130 |
Why?
| | Benzimidazoles | 1 | 2017 | 138 | 0.130 |
Why?
| | Skin | 1 | 2020 | 659 | 0.130 |
Why?
| | Vaccination | 2 | 2020 | 1205 | 0.130 |
Why?
| | Recurrence | 1 | 2018 | 936 | 0.130 |
Why?
| | Incidence | 2 | 2020 | 2312 | 0.130 |
Why?
| | Midwestern United States | 1 | 2015 | 38 | 0.130 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1435 | 0.130 |
Why?
| | Viral Load | 1 | 2017 | 405 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 1214 | 0.120 |
Why?
| | Surveys and Questionnaires | 4 | 2015 | 4622 | 0.120 |
Why?
| | Health Promotion | 1 | 2021 | 686 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2020 | 2538 | 0.120 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 954 | 0.120 |
Why?
| | Amphotericin B | 1 | 2014 | 29 | 0.120 |
Why?
| | RNA, Viral | 1 | 2017 | 566 | 0.110 |
Why?
| | Epidemiologic Methods | 1 | 2014 | 72 | 0.110 |
Why?
| | Antifungal Agents | 1 | 2014 | 128 | 0.110 |
Why?
| | Social Stigma | 1 | 2014 | 87 | 0.100 |
Why?
| | Early Diagnosis | 1 | 2014 | 216 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1477 | 0.100 |
Why?
| | Professional-Patient Relations | 1 | 2014 | 141 | 0.100 |
Why?
| | Genotype | 1 | 2017 | 1773 | 0.100 |
Why?
| | Physicians | 1 | 2020 | 772 | 0.100 |
Why?
| | Physicians, Primary Care | 1 | 2014 | 222 | 0.100 |
Why?
| | Advance Care Planning | 1 | 2014 | 197 | 0.100 |
Why?
| | Internal Medicine | 1 | 2013 | 211 | 0.090 |
Why?
| | North America | 2 | 2023 | 257 | 0.090 |
Why?
| | Fear | 1 | 2014 | 292 | 0.090 |
Why?
| | Infant, Newborn | 1 | 2021 | 5034 | 0.090 |
Why?
| | Recreation Therapy | 1 | 2010 | 2 | 0.090 |
Why?
| | Pregnancy, High-Risk | 1 | 2010 | 12 | 0.090 |
Why?
| | Evidence-Based Practice | 2 | 2023 | 185 | 0.090 |
Why?
| | Bed Rest | 1 | 2010 | 15 | 0.090 |
Why?
| | Decision Making | 1 | 2016 | 781 | 0.090 |
Why?
| | Music Therapy | 1 | 2010 | 22 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 370 | 0.080 |
Why?
| | Chronic Disease | 1 | 2014 | 1590 | 0.080 |
Why?
| | Internship and Residency | 2 | 2014 | 932 | 0.070 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 977 | 0.070 |
Why?
| | Counseling | 1 | 2009 | 342 | 0.070 |
Why?
| | Anorexia | 1 | 2005 | 18 | 0.060 |
Why?
| | Pregnancy Complications | 1 | 2010 | 429 | 0.060 |
Why?
| | Cachexia | 1 | 2005 | 52 | 0.060 |
Why?
| | Recovery of Function | 1 | 2008 | 572 | 0.060 |
Why?
| | Patient Education as Topic | 1 | 2009 | 679 | 0.060 |
Why?
| | Healthcare Disparities | 1 | 2009 | 479 | 0.060 |
Why?
| | Treatment Outcome | 1 | 2017 | 9089 | 0.060 |
Why?
| | Neoplasms | 2 | 2008 | 2105 | 0.060 |
Why?
| | Government | 1 | 2022 | 10 | 0.050 |
Why?
| | Kentucky | 1 | 2022 | 35 | 0.050 |
Why?
| | Organizations | 1 | 2022 | 19 | 0.050 |
Why?
| | Public Opinion | 1 | 2022 | 59 | 0.050 |
Why?
| | Stress, Psychological | 1 | 2010 | 944 | 0.050 |
Why?
| | Syringes | 1 | 2022 | 41 | 0.050 |
Why?
| | Immunization, Secondary | 1 | 2022 | 82 | 0.050 |
Why?
| | Oregon | 1 | 2021 | 66 | 0.050 |
Why?
| | Public Health Practice | 1 | 2022 | 61 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 124 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2009 | 1183 | 0.050 |
Why?
| | British Columbia | 1 | 2020 | 10 | 0.050 |
Why?
| | Infectious Disease Medicine | 1 | 2020 | 10 | 0.050 |
Why?
| | Health Care Rationing | 1 | 2020 | 45 | 0.050 |
Why?
| | Human Rights | 1 | 2020 | 15 | 0.050 |
Why?
| | Invasive Fungal Infections | 1 | 2020 | 10 | 0.050 |
Why?
| | Federal Government | 1 | 2020 | 26 | 0.050 |
Why?
| | Delayed-Action Preparations | 1 | 2021 | 159 | 0.040 |
Why?
| | New York | 1 | 2020 | 106 | 0.040 |
Why?
| | State Government | 1 | 2020 | 41 | 0.040 |
Why?
| | Methadone | 1 | 2021 | 77 | 0.040 |
Why?
| | Canada | 1 | 2021 | 322 | 0.040 |
Why?
| | Hepatitis B | 1 | 2020 | 51 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2020 | 130 | 0.040 |
Why?
| | Health Education | 1 | 2022 | 324 | 0.040 |
Why?
| | Specialization | 1 | 2020 | 114 | 0.040 |
Why?
| | Infection Control | 1 | 2020 | 135 | 0.040 |
Why?
| | Bacteremia | 1 | 2020 | 159 | 0.040 |
Why?
| | Regression Analysis | 1 | 2020 | 946 | 0.040 |
Why?
| | Patient Compliance | 1 | 2022 | 525 | 0.040 |
Why?
| | Leadership | 1 | 2020 | 292 | 0.040 |
Why?
| | Communication | 1 | 2022 | 747 | 0.040 |
Why?
| | Prospective Studies | 2 | 2023 | 6216 | 0.040 |
Why?
| | Societies, Medical | 1 | 2020 | 663 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1126 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1270 | 0.030 |
Why?
| | Patient Readmission | 1 | 2020 | 608 | 0.030 |
Why?
| | Patient Discharge | 1 | 2020 | 768 | 0.030 |
Why?
| | Behavior Therapy | 1 | 2014 | 226 | 0.030 |
Why?
| | Focus Groups | 1 | 2013 | 385 | 0.020 |
Why?
| | Watchful Waiting | 1 | 2010 | 55 | 0.020 |
Why?
| | Qualitative Research | 1 | 2013 | 935 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2005 | 50 | 0.020 |
Why?
| | Psychometrics | 1 | 2005 | 607 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2008 | 2762 | 0.010 |
Why?
| | Pregnancy | 1 | 2010 | 5524 | 0.010 |
Why?
| | Prognosis | 1 | 2005 | 3334 | 0.010 |
Why?
| | Risk Assessment | 1 | 2005 | 2973 | 0.010 |
Why?
|
|
Barocas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|